1 **Title:** Acute glutamine supplementation does not improve 20-km self-paced cycling performance in the heat.

2 **Running heading:** Glutamine does not improve cycling in the heat.

3

4 **Authors:** John O. Osborne^{1,2}, Ian B. Stewart^{1,2}, Kenneth W. Beagley^{2,3}, David N. Borg^{1,2,4}, Geoffrey M.

5 Minett^{1,2}.

6

7 **Affiliations**

8 ¹School of Exercise and Nutrition Sciences, Queensland University of Technology (QUT), Brisbane, Australia.

9 ²Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Brisbane,
10 Australia.

11 ³School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, Australia.

12 ⁴The Hopkins Centre, Menzies Health Institute Queensland, Griffith University, Brisbane, Australia.

13

14 **Corresponding Author**

15 John O. Osborne

16 School of Exercise and Nutrition Sciences and Institute of Health and Biomedical Innovation, Queensland
17 University of Technology (QUT), Queensland, Australia.

18 Address: 60 Musk Avenue, Kelvin Grove, Brisbane, Queensland, Australia, 4059.

19 ORCID: 0000-0001-8681-8521

20

21 **Funding:** None declared.

22 **Competing Interests:** None declared.

23

24 **Abbreviations**

25	½ RT	half relaxation time
26	20TT	20 km time trial
27	CD	contraction duration
28	CI	credible interval
29	CON	control
30	CNS	central nervous system
31	CV	coefficient of variation
32	ELISA	enzyme-linked immunosorbent assay
33	EMG	electromyography
34	GI	gastrointestinal
35	GLUT	glutamine
36	HR	heart rate
37	ICC	intraclass correlation
38	I-FABP	intestinal fatty acid binding protein
39	IL-6	interleukin 6
40	MCMC	Markov chain Monte Carlo
41	MD	mean difference
42	MVC	maximum voluntary contraction
43	POMS	profile of mood states
44	Pt	peak torque
45	Pr	probability
46	RPE	Rating of Perceived Exertion
47	RR	rate of relaxation
48	RTD	rate of torque development
49	SESOI	smallest effect size of interest
50	T _{re}	core (rectal) temperature
51	TNF- α	tumour necrosis factor alpha
52	TPt	time to peak torque
53	T _{sk}	mean skin temperature

54	USG	urine specific gravity
55	VA	voluntary activation
56	VL	vastus lateralis
57	VM	vastus medialis
58	VO _{2max}	maximal aerobic capacity

59 **ABSTRACT**

60 *Introduction:* The premise of this study was to investigate the effect of acute glutamine supplementation on 20
61 km time trial cycling performance in the heat, neuromuscular function, inflammation and endotoxemia.

62

63 *Methods:* Twelve cyclists completed two, 20-km time trials (20TT) in 35 °C (50% relative humidity). Participants
64 ingested either glutamine (GLUT; 0.9 g·kg⁻¹ fat-free mass) or a placebo (CON) 60 min before each 20TT.
65 Physiological and perceptual measures were recorded during each 20TT, and neuromuscular function assessed
66 pre- and post-exercise. Venous blood was analysed for endotoxins, markers of gut damage (inflammatory fatty
67 acid binding protein; I-FABP) and inflammatory cytokines (interleukin-6, IL-6; tumour necrosis factor-alpha,
68 TNF-α). Data were analysed using linear mixed models in a Bayesian framework.

69

70 *Results:* 20TT in the heat increased I-FABP and elevated inflammatory cytokines (IL-6 and TNF-α) compared to
71 pre-exercise values but did not result in endotoxemia. Completion time was not statistically different between
72 conditions (mean difference [95% credible interval] = 11 s [-23, 44]). Relative to CON, GLUT did not alter any
73 physiological or perceptual measures during the 20TT.

74

75 *Conclusion:* Glutamine supplementation does not improve 20TT performance in the heat or preserve
76 neuromuscular function when compared to a placebo. These findings suggest that glutamine is not an ergogenic
77 aid or prophylactic intervention for heat-induced gut damage during short-duration self-paced exercise in hot
78 environments.

79

80 **KEYWORDS**

81 Glutamine, Exercise, Endotoxemia, Hyperthermia, Inflammation

82

83 1. INTRODUCTION

84 Hot environmental conditions hinder endurance exercise performance (Galloway & Maughan, 1997; Tatterson,
85 Hahn, Martini, & Febbraio, 2000) and multiple causative factors may contribute to the premature development of
86 fatigue (Nybo, Rasmussen, & Sawka, 2014). One proposed pathway, the ‘neuroinflammatory model’, links
87 hyperthermic-impairments in gastrointestinal (GI) blood flow and death of GI cells (Lambert, 2008) with the
88 translocation of endotoxins and release of pro-inflammatory cytokines into systemic circulation (e.g., interleukin-
89 6 (IL-6) and tumour necrosis factor-alpha (TNF- α) (Lim & Mackinnon, 2006). Elevated circulating levels of these
90 inflammatory cytokines have been connected to transient fatigue-like symptoms and altered motivational states
91 (Dantzer, 2004). These cytokines are also theorised to contribute to a downregulation of neural drive to the skeletal
92 muscle, impairing exercise performance in the heat (Vargas & Marino, 2014).

93

94 Elevated markers of GI damage, endotoxins and inflammatory cytokines have been repeatedly detected in athletes
95 following prolonged (~3-7 h) endurance competition in thermally stressful environments (Camus et al., 1997; Gill
96 et al., 2015; Økstedalen, Lunde, Opstad, Aabakken, & Kvernebo, 1992). Similarly, increases in some, or all, of
97 these variables have also been reported after short-duration (~20-134 min), fixed-intensity exercise in simulated
98 hot environments (Marchbank et al., 2011; Osborne, Stewart, Beagley, & Minett, 2019; Pugh, Impey, et al., 2017;
99 Selkirk, McLellan, Wright, & Rhind, 2008). Based on this previous research, it is plausible that short-duration
100 self-paced exercise in the heat may also result in GI damage, exertional-endotoxemia and impaired performance.
101 However, the external validity of fixed-paced tasks in the heat has been previously criticised, as constant work
102 rates preclude the anticipatory behavioural regulation from afferent feedback and/or pacing strategy in self-paced
103 exercise trials (Tucker, 2008). As such, the effect of short-duration time-trial tasks in the heat on GI damage,
104 endotoxemia, inflammation and central fatigue remains to be elucidated.

105

106 If short-duration self-paced exercise in the heat does result in heat-induced GI damage, preventative interventions
107 that protect the GI barrier have the potential to mitigate this negative feed-forward loop and improve exercise
108 performance (Guy & Vincent, 2018; Lambert, Broussard, Mason, Mauermann, & Gisolfi, 2001). Glutamine, a
109 non-essential amino acid, has been found to augment the intestinal barrier and protect against septic shock in
110 clinical populations (Castell, 2003; De-Souza & Greene, 2005), and reduce intestinal damage and permeability
111 during exertional heat-stress (Pugh, Sage, et al., 2017; Zuhl et al., 2015; Zuhl et al., 2014). Glutamine’s role in
112 stabilising the intestinal lining appears multifactorial, with two distinct pathways proposed by which it may

regulate barrier function: providing an essential energy source for gut mucosal epithelial cells; and enhanced expression of transmembrane proteins which form tight junctions along the intestinal barrier (Rao & Samak, 2012).

Previous studies have primarily focused on the mechanistic application of glutamine on GI function during fixed-pace exercise tasks, rather than the potentially ergogenic effect on self-paced performance (Lambert et al., 2001; Pugh, Sage, et al., 2017; Zuhl et al., 2015; Zuhl et al., 2014). While the occurrence of GI damage and exertional endotoxemia during short-duration, self-paced exercise in the heat is currently unknown, it could be postulated that glutamine supplementation may protect against possible GI damage and pro-inflammatory cytokine release during exercise in the heat. As elevated levels of inflammatory cytokines have been implicated in fatigue-like sensations (i.e., reduced motivation) and impaired efferent drive (Vargas & Marino, 2017; Vargas & Marino, 2014), a glutamine-mediated reduction in these cytokines may preserve voluntary activation of skeletal muscle and, therefore, positively influence exercise performance.

The current study aimed to investigate the effect of acute glutamine supplementation on 20 km time trial cycling performance in the heat. A secondary aim was to investigate the effect of glutamine supplementation on neuromuscular function, inflammation and endotoxemia. It was hypothesised that glutamine would improve exercise performance (i.e., faster time trial completion) and preserve neuromuscular function in association with an attenuation of the development of central fatigue. Further, glutamine supplementation would maintain intestinal barrier integrity, observable via a diminished level of circulating endotoxins, inflammatory cytokines, markers of GI damage and subjective GI symptoms.

2. METHODS

2.1 Participants

A convenience sample of twelve male cyclists (mean $\pm$ standard deviation); age: 32 ± 6 y, body mass: 78 ± 8 kg, fat-free mass: 65 ± 6 kg, $\text{VO}_{2\text{max}}$: 61.0 ± 6.2 mL $\cdot$ kg $^{-1}\cdot$ min $^{-1}$, $\text{Power}_{\text{max}}$: 430 ± 48 W; HR_{max} : 189 ± 8 beats $\cdot$ min $^{-1}$) volunteered to participate in this study. All participants cycled at least twice per week (distance: 225 ± 93 km $\cdot$ wk $^{-1}$) and were classified as trained or well-trained athletes (performance level 3 or 4) (De Pauw et al., 2013). Participants were non-smokers, free of any injury or illnesses, reported no history of GI or kidney diseases and were consuming no other supplements. All participants were informed of the study requirements and procedures

before obtaining written and verbal consent. The University Human Research Ethics Committee approved this project before the commencement of any testing (Approval #: 1700000620).

2.2 Experimental overview

Participants visited the laboratory on three separate occasions; an initial familiarisation trial followed by two experimental trials, involving glutamine supplementation (GLUT) or a placebo control (CON). The familiarisation trial involved an incremental maximal aerobic capacity test (VO_{2max}), followed by neuromuscular testing practice and a 20 km time trial (20TT). The experimental trials were completed in a double-blind, randomised, crossover manner, each separated by ≥ 7 days. All testing sessions involved a 20TT undertaken in environmental conditions of 35.1 ± 0.5 °C and $51 \pm 4\%$ relative humidity. Participants were asked to diarise their food and fluid intake for 24 h, and their physical activity for 48 h, before the first experimental trial and to replicate this for the subsequent trial. Participants were also asked to abstain from caffeine and alcohol for 12 h, and strenuous physical activity for 48 h before each experimental trial. Compliance to these requests was verbally assessed before each trial. A schematic for the experimental trials is shown in Fig. 1.

Figure 1. Experimental trial schematic. Participants completed both conditions in a double-blind, randomised, crossover manner, each separated by ≥ 7 days.

2.3 Experimental trials

Each experimental trial was matched for the time of day (± 2 h), and upon arrival, participants ingested a GLUT or CON solution from an opaque drink bottle. The GLUT solution comprised of powdered glutamine ($0.9 \text{ g} \cdot \text{kg}^{-1}$ of fat-free mass; L-Glutamine; Bulk Nutrients, Grove, Australia) mixed with 450 mL of room-temperature water and 50 mL of sugar-free lemon cordial (Diet Rite, Tru Blu Beverages, Bundamba, Australia). This dosage has been previously shown to attenuate GI permeability when compared to a placebo (Pugh, Sage, et al., 2017; Zuhl et al., 2015). The CON beverage contained matched fluid volume (i.e., water and cordial) but was void of any supplement. Body mass, fat mass and fat-free mass were measured during the familiarisation trial to calculate the supplement dose using multi-frequency bioelectrical impedance analysis (MC-780MA; Tanita Corp., Tokyo, Japan). All solutions were independently mixed immediately before ingestion, to limit glutamine degradation in the aqueous solution.

Participants provided urine and blood samples and consumed the supplement drink before undertaking a pre-exercise neuromuscular test. This was followed by nude body mass weigh, instrumentation and completion of pre-trial forms (i.e., 24-h dietary recall, 48-h physical activity recall, profile of mood states questionnaire (POMS)). All participants wore cycling apparel (i.e., bib, socks and cycling shoes). Participants were seated for 5 min in a climate-controlled laboratory (24.2 ± 1.0 °C, $60 \pm 4\%$ relative humidity) and baseline physiological (i.e., resting T_{e} , T_{skin} , HR) and perceptual (i.e., thermal sensation, thermal comfort) data collected. Participants then entered a climate-controlled chamber (35.1 ± 0.5 °C, $51 \pm 4\%$ relative humidity) and completed a 20TT. All 20TTs were completed on a Velotron Pro cycle ergometer (RacerMate Inc., Washington, USA), commencing from a seated, stationary position. Velotron 3D software (Version NB04.1.0.2101, RacerMate Inc., Washington, USA) provided elapsed distance feedback over a computer-simulated flat cycling course. A constant background scene was shown, and no simulated wind resistance or computer opponents were displayed. Participants were instructed to complete the 20 km distance as quickly as possible and could freely alter gearing using a hood-mounted toggle-switch. Performance feedback was withheld during both 20TTs, and provided only after study completion. Highly reliable 20TT performance results (intra-class correlation; ICC = .93; coefficient of variation; CV = 0.9%) are reported using familiarised, trained cyclists in our laboratory (Borg et al., 2018). The time delay between completion of the supplement consumption and commencement of the 20TT was 61 ± 7 min. This lead-in time was chosen to align with peak plasma glutamine concentrations as reported in previous research (Ziegler et al., 1990). All fluid was withheld during 20TT and until after the collection of post-exercise measures.

2.4 Thermophysiological measures

Heart rate (HR) was recorded using a chest strap (Polar Electro Oy, Kempele Finland) and software (Polar Team², Kempele Finland). Core (rectal) temperature (T_{re}) was assessed via a thermistor (449H; Henleys Medical, Hertfordshire, UK) inserted 12 cm beyond the anal sphincter and connected to a wireless data logger (T-Tec 7 RF 7-3E) set to record every 2 s. No participant reached the T_{re} termination threshold of 40 °C during the exercise bout.

Skin temperature was recorded at 5 s intervals with wireless iButton thermocrons (DS1922L-F50 iButtons, Maxim Integrated, San Jose, USA) attached with adhesive tape (Leuko Sportstape Premium; Beiersdorf, Hamburg, Germany) to four sites: posterior neck, right scapula, posterior left hand and mid-anterior shin. Mean skin temperature (T_{sk}) was calculated according to the published four-site formula (ISO 9886, 2004).

A mid-stream urine sample was collected at the start of each experimental trial to assess specific gravity (PAL-10S; Atago Co. Ltd, Tokyo, Japan) and urine colour (scale: 1-8 AU) (Armstrong et al., 2010). Body fluid loss was calculated via pre- to post-exercise nude weight change, using calibrated scales (WB-110AZ; Tanita Corp., Tokyo, Japan).

Perceptual measures were recorded every 2 km during each 20TT. These included Borg's 15-point rating of perceived exertion (RPE) scale (Borg, 1998), a 16-point thermal sensation scale ranging from 0 'unbearably cold' to 8 'unbearably hot' (Young, Sawka, Epstein, Decristofano, & Pandolf, 1987), and a modified 10-point thermal comfort scale ranging from 1 'comfortable' to 5 'extremely uncomfortable' (Gagge, Stolwijk, & Hardy, 1967). After the post-exercise blood draw, participants completed a post-trial GI distress form (adapted from Pfeiffer, Cotterill, Grathwohl, Stellingwerff, and Jeukendrup (2009) to assess the incidence of GI symptoms and severity on a 100 point scale (0 = none; 100 = severe), and provided a session RPE (sRPE) (Foster et al., 2001).

2.5 Neuromuscular function

The neuromuscular function of the right knee extensor muscles was assessed pre- and immediately post-exercise using a Biodex System 3 dynamometer (Biodex Medical Systems, Shirley, New York, USA). Participants were seated in an upright position with the back of the chair adjusted to 95° from horizontal and the lever fulcrum aligned with the right lateral epicondyle of the femur. Participants were secured using chest, waist, right thigh and

ankle straps. Voluntary activation (VA) of the knee extensors was assessed using the twitch interpolation technique on the right femoral nerve. Self-adhesive gel electrodes (Pals; Axelgaard Manufacturing Co. Ltd., Fallbrook, CA) were positioned on the right femoral triangle and the border of the right gluteal fold. The current was applied to the nerve by a Digitimer DS7AH stimulator (Digitimer Ltd., Welwyn Garden City, Hertfordshire, England) using a single, 100 μ s, square-wave pulse. A twitch ramp procedure was completed at the start of each trial with a stimulus of increasing current delivered to a resting muscle until a plateau in twitch torque was observed, and then increased by an additional 10% to ensure supramaximal stimulation.

Participants undertook a standardised warm-up before completing a set of five, 5 s maximal voluntary isometric knee extensions (MVC) at 90° knee flexion, with a 30 s rest between each repetition. Participants received loud verbal encouragement to maximally contract and visual feedback of their torque. The primary investigator manually triggered a femoral nerve stimulation when the participant demonstrated a plateau in MVC torque during each repetition. An additional resting stimulation was triggered upon the completion of each MVC to assess peripheral contractile properties. Another set of five, 5 s MVCs with stimulation were completed immediately post-exercise.

The twitch interpolation formula used to calculate VA was: $VA (\%) = (1 - \text{amplitude}/\text{resting control twitch torque}) * 100$ (Allen, Gandevia, & McKenzie, 1995). Only MVC repetitions that demonstrated a torque plateau were included in VA calculations. MVC torque was considered the mean torque value of 25 ms preceding the interpolated twitch, and the peak torque recorded in the 100 ms following the stimulus was considered the superimposed torque. The difference between the MVC torque and the superimposed torque was considered the amplitude. Participants were extensively familiarised with all neuromuscular testing procedures during the initial laboratory visit and were able to reproduce similar MVC torque values consistently with a CV of 5.6%. These neuromuscular assessments of MVC torque and VA are highly reliable by our laboratory, with calculated ICC's of .94 and .94, respectively. Evoked twitch contractile data were averaged for each time point and analysed for peak twitch torque (Pt; maximum evoked twitch torque); time to peak torque (TPt; time from torque onset to Pt); half relaxation time ($\frac{1}{2}$ RT; time for torque to decrease by half of Pt); contraction duration (CD; TPt plus $\frac{1}{2}$ RT); rate of torque development (RTD; slope of twitch-torque curve from onset to Pt); rate of relaxation (RR; slope of twitch-torque curve from Pt to $\frac{1}{2}$ RT).

2.6 Surface electromyography (EMG)

Muscle activation of the right vastus medialis (VM) and vastus lateralis (VL) were measured using surface EMG during the neuromuscular assessments. All sites were shaved, abraded and swabbed with alcohol before electrode placement. Electrodes (Ambu Blue Sensor N-00-S; Ambu A/S, Ballerup, Denmark) were positioned parallel with the muscle fibres, and an earth electrode was attached to the lateral femoral epicondyle. Electrodes remained attached during the 20TT to ensure consistency between the pre- and post-neuromuscular assessments. EMG data were sampled at 1 kHz through a 16-bit PowerLab 26T AD unit (AD Instruments, Sydney, Australia) (amplification=1000; common mode rejection ratio=110 dB) and band-pass filtered (20-500 Hz). Raw EMG data were smoothed using the RMS method (100 ms window) through LabChart 8.1.5 software (AD Instruments, New South Wales, Australia). Voluntary muscle activation was considered the mean smoothed EMG value of a 500 ms period preceding each interpolated stimulus. Post-exercise EMG amplitudes were compared as a relative change to the mean values obtained during pre-exercise MVCs and presented as a percentage.

2.7 Blood markers

Pre- and post-exercise blood samples were drawn from an antecubital venipuncture using a butterfly needle (21G, BD, North Ryde, Australia) into EDTA vacutainer tubes (BD, North Ryde, Australia) and immediately centrifuged at 3500 RPM for 15 min at 4 °C. Following centrifugation, pyrogen-free aliquots of plasma were frozen at -80°C for a maximum of 6 months before analysis.

Circulating IL-6 (HS600B; R&D Systems, Minneapolis, USA), TNF- α (EK-0001; elisakit.com, Melbourne, Australia), and inflammatory fatty acid binding protein (I-FABP) (EHFABP2; Thermo Scientific, Fredrick, USA) concentrations were determined using quantitative sandwich enzyme-linked immunoassay assays (ELISA), prepared in accordance with the manufacturer's protocols. All samples were diluted to reduce interference and avoid a matrix effect. Absorbance was quantified using a SpectroStar Nano (BMG Labtech, Offenburg, Germany) with wavelength subtraction to correct for optical imperfections in the plates. Intra-assay CV was calculated as 8.0% (IL-6), 8.0% (TNF- α) and 7.1% (I-FABP), respectively.

Endotoxin concentrations were quantified using a kinetic chromogenic *Limulus* amoebocyte lysate (LAL) assay kit (50-650U), as instructed by the manufacturer (Lonza, Walkersville, USA). In short, the *E. coli* 055:B5 endotoxin standard was reconstituted with LAL reagent water and vortexed for 15 min to produce a 50 EU·mL⁻¹ stock

solution. Serial dilutions of this stock standard (5, 0.5, 0.05, 0.005 EU·mL⁻¹) were prepared in duplicate, with each solution vortexed for at least 2 min between dilutions. Plasma samples were heated for 45 min at 75 °C to inactivate endotoxin-neutralising agents and diluted at 1:10 with magnesium chloride (MgCl) to overcome chelation from EDTA. Plates were incubated for 20 min at 37 °C in a SpectroStar Nano (BMG Labtech, Offenburg, Germany) before the addition of 100 µL of reconstituted Kinetic-QCL™ Reagent to each well. Plates were then read at 405 nm, and this was repeated every 61 s for 118 cycles. A log/log (time for the sample to increase 0.2 absorbance units/concentration) linear correlation of each standard was calculated ($r = -0.999$) to determine the sample concentration. Sterile tips (Biopur epTIPS; Eppendorf AG, Germany) were used for all pipetting to reduce endotoxin contamination.

2.8 Data Analysis

Data were analysed using linear mixed models in a Bayesian framework (Mengersen, Drovandi, Robert, Pyne, & Gore, 2016). Exploratory plots were inspected for normality before Markov chain Monte Carlo (MCMC, 50k iterations, 1k burn-in, thinned by a factor of 10) procedures generated posterior predicted values using the ‘rjags’ and ‘R2jags’ packages in R (Mengersen et al., 2016). Models utilised vague prior distributions for each regression coefficient (mean 0, precision 0.001) and each variance parameter (shape 0.01, scale 0.01). Models included *time*, *condition* and *time x condition* as fixed factors. When there was no evidence of a *time x condition* intervention, the term was removed from the final model.

Posterior estimates of interest were: mean and 95% credible interval [CI]; mean difference (MD, and associated 95% CI) between conditions or time points of interest; and Cohen’s *d*, where $\sqrt{\text{Var}(k - l)}$ was the denominator for *d* when comparing conditions or time points *k* and *l* (Cohen, 1988). Where the 95% CI (of a regression coefficient or MD) did not include zero, there was sufficient evidence of a statistical effect or difference. Cohens *d* values were interpreted as small (0.20 – 0.49), moderate (0.50 – 0.79) and large (≥ 0.80) (Cohen, 1988). Primary outcomes of interest in this study were considered: MVC torque, VA, I-FABP and TNF- α . For these variables, we also calculated the probability that the within-condition difference exceeded the smallest effect size of interest (SESOI), denoted as $d < -\text{SESOI}$ or $d > \text{SESOI}$, depending on the direction of the difference. The SESOI for MVC and VA was: -1.33 and -0.51 (Périard, Christian, Knez, & Racinais, 2014; Périard, Cramer, Chapman, Caillaud, & Thompson, 2011); for I-FABP: 2.66 (Pugh, Impey, et al., 2017; Pugh, Sage, et al., 2017; van Wijck et al., 2011);

and for $\text{TNF-}\alpha$: 0.44 (Lim et al., 2009; Zuhl et al., 2015). The convergence of MCMC to the posterior was visually assessed via trace plots, and posterior predictive checks were performed for all models.

3. RESULTS

No statistical differences in mood (i.e., POMS) upon arrival or baseline hydration measures (USG and urine colour) were observed between conditions (Table 1). Pre-exercise body mass, resting T_{re} and T_{sk} were also similar between conditions (Table 1). The absence of any statistical difference in baseline measures indicates that participants commenced each 20TT in a similar psychological and physiological state.

Post-exercise fluid loss, both absolute and relative, were not statistically different between conditions (GLUT = 1.3 kg loss [1.0, 1.3] and 1.5% loss [1.3, 1.7]; CON = 1.3 kg loss [1.1, 1.4] and 1.6% loss [1.4, 1.8]; Table 1). Although there was some indication for a higher severity of reported symptoms in CON, the incidence of GI symptoms was not found to be statistically different between conditions (Table 2). Supplementation did not affect sRPE following each 20TT (Table 1). Participants were successfully blinded to the intervention with a calculated James's Blind Index of .67 [.48, .85] (James, Bloch, Lee, Kraemer, & Fuller, 1996).

3.1 Exercise

There was no statistical evidence to suggest that glutamine supplementation affected 20TT completion time, with a mean difference [95% CI] of 11 s [-23, 44] between conditions. No statistical differences in mean 20TT power, cadence and speed between the two conditions were observed (Table 3). Statistical analysis revealed only a *time* effect for HR, T_{re} , T_{sk} , RPE, thermal sensation and thermal comfort over the 20TT (Table 3).

3.2 Neuromuscular function and EMG

The 20TT reduced VA impairment, from pre-exercise values for both CON (-5.6% [-1.9, -9.5]; $d = -3.0$) and GLUT (-5.2% [-1.5, -8.8]; $d = -2.8$), and this was supported by a high probability that $d < -\text{SESOI}$ (-0.51) for both conditions (CON = .99; GLUT = .98). No between-condition difference was found for VA. A *time* effect was identified for MVC torque, although a large reduction was only observed pre- to post-exercise for CON (MD [95% CI] = -24 N·m [-40, -7]; d [95% CI] = -2.8 [-4.8, 0.9]), with a smaller decrease for GLUT (MD [95% CI] = -11 N·m [-28, 5]; d [95% CI] = -1.4 [-3.4, 0.6]; Figure 2). The probability that $d < -\text{SESOI}$ for these within-condition comparisons was .94 and .48, respectively. Evidence of a *time* effect was found for the remaining muscle

contractile properties of Pt, TPt, ½ RT, RR and CD, which were reduced from initial values (Table 4), with no *condition* effect. There was no indication of *time*, *condition* or *time* x *condition* effects for muscle activation (relative %EMG of VL and VM) or RTD (Table 4).

Figure 2. Neuromuscular function of the knee extensors pre and post-20TT following ingestion of glutamine (GLUT) or placebo (CON). Data displayed as posterior predicted mean ± 95% credible interval and overlaid with raw individual responses. * indicates a *time* effect.

3.3 Blood markers

Cycling in the heat statistically increased concentrations of IL-6 compared to pre-exercise levels for both GLUT (MD [95% CI] = 2.7 pg·mL⁻¹ [1.4, 4.0]; *d* [95% CI] = 4.1 [2.1, 6.1]) and CON (MD [95% CI] = 3.2 pg·mL⁻¹ [1.9, 4.6]; *d* [95% CI] = 4.7 [2.7, 6.7]), though no *condition* or *time* x *condition* effects were observed (Figure 3; Table 5). A *time* effect was detected for plasma TNF-α levels, with an increase from pre-exercise values for CON (MD [95% CI] = 1.8 pg·mL⁻¹ [0.5, 3.1]; *d* [95% CI] = 2.7 [0.7, 4.7]), but there was little evidence for GLUT (MD [95% CI] = 0.5 pg·mL⁻¹ [-0.8, 1.9]; *d* [95% CI] = 0.7 [-1.2, 2.8]). While no *condition* or *interaction* effects were observed for TNF-α, the probability that the within-condition *d* > SESOI was .99 for CON and .60 for GLUT, providing some evidence towards a possible condition difference. A similar finding was observed for I-FABP, with evidence of a clear *time* effect for CON (MD [95% CI] = 0.441 ng·mL⁻¹ [0.235, 0.656]; *d* [95% CI] = 4.1 [2.2, 6.1]), but less so for GLUT (MD [95% CI] = 0.206 ng·mL⁻¹ [-0.025, 0.418]; *d* [95% CI] = 1.9 [0.0, 3.9]). The probability that the within-condition *d* > SESOI was .99 for CON and .32 for GLUT. No *condition*, *time*, or *time* x *condition* effects were observed for endotoxin.

Figure 3. Plasma concentration of: (a) TNF- α ; (b) IL-6; and (c) I-FABP at pre- and post-20TT time points.

Data displayed as posterior predicted mean $\pm$ 95% credible interval and overlaid with raw individual responses.

* indicates a *time* effect.

4. DISCUSSION

A primary finding from this study was that 30-40 min of self-paced exercise in the heat resulted in an apparent increase in markers of GI damage and inflammation, indicating that athletes competing in short-duration events experience sufficient thermal and cardiovascular stress to injure the intestinal barrier (Figure 3). These data align with the increased GI damage and permeability previously reported in research utilising both fixed paced protocols of between 20-60 mins (Lambert et al., 2008; Marchbank et al., 2011; Morrison, Cheung, & Cotter, 2014; Pugh, Impey, et al., 2017) and long-duration endurance events of 3-8 hours (Lambert et al., 1999; Øktedalen et al., 1992).

In contrast to the study hypothesis, no change in endotoxin levels were detected after a 20TT in the heat (Table 5). This outcome was unexpected, given that exertional-endotoxemia has been previously observed following strenuous exercise in the heat, in both prolonged competitive events (Camus et al., 1997; Gill et al., 2015; Jeukendrup et al., 2000) and shorter-duration, fixed-intensity studies (Lim et al., 2009; Selkirk et al., 2008; Yeh, Law, & Lim, 2013). One possible explanation may be that the relative brevity of the current exercise task (i.e., ~33 min) only resulted in limited translocation of endotoxins, which could be quickly inactivated and neutralised by anti-LPS antibodies and low-density lipoproteins (Lim & Mackinnon, 2006). In contrast, the longer-duration exercise task used in previous research appears to overload the limited capacity of these clearance mechanisms, resulting in detectable endotoxemia (Bosenberg, Brock-Utne, Gaffin, Wells, & Blake, 1988; Brock-Utne et al., 1988; Camus et al., 1998).

The current study also provided evidence that acute glutamine supplementation does not alter completion time, mean power, speed or cadence during a 20 km self-paced cycling trial in the heat (Table 3). This outcome was reflected in the comparable values of physiological and perceptual strain for CON and GLUT over the 20TT. Furthermore, glutamine supplementation was not found to preserve VA more than the placebo, with a similar statistical reduction in VA observed in both conditions following the 20TT (Table 4). These data suggest athletes competing in shorter-duration events (i.e., criterium racing) in the heat are unlikely to obtain a performance benefit from glutamine supplementation. No *condition* or *time* x *condition* effects were observed for MVC torque, I-FABP and TNF- α , although this may have been due to the sample size, as within-condition effect sizes appeared to diverge between GLUT and CON (Table 4 and 5). Speculatively, the low probability that effect sizes for GLUT exceeded each respective SESOI could be considered preliminary evidence that glutamine may potentially preserve knee extensor torque ($d = -1.4$; $\text{Pr } d < -\text{SESOI} (-1.3) = .48$) and protect against GI damage ($d = 1.9$; $\text{Pr } d$

> SESOI (2.7) = .32). As endotoxin translocation was not observed during the current study, possibly due to the short duration, the previously-hypothesised effect of glutamine supplementation on endotoxin translocation remains to be elucidated (Lambert, 2009). Future research should continue to explore the possible relationship between glutamine and endotoxin levels during longer-duration self-paced tasks.

Cycling in a hot environment for 20 km statistically reduced MVC torque compared to pre-exercise values (Figure 2). Périard and colleagues (2011) observed similar impairments in voluntary torque following a 40 km cycling time trial in the heat, with the authors implicating the prolonged dynamic muscular contractile activity of the exercise task. In particular, high muscle temperatures have been shown to result in more responsive contractile properties, namely a faster TPT and $\frac{1}{2}$ RT (Todd, Butler, Taylor, & Gandevia, 2005). A similar occurrence was seen in the current study, with a faster TPT and $\frac{1}{2}$ RT was observed for both conditions, and these data support the similar post-exercise MVC torque between conditions. Conversely, there was some evidence for a greater loss of torque in CON ($d = -2.8$; $\text{Pr } d < -\text{SESOI} (-1.3) = .94$) than in GLUT ($d = -1.4$; $\text{Pr } d < -\text{SESOI} (-1.3) = .48$) post-exercise. However, as the similar decrease in VA and Pt for both conditions implies a comparable development of central and peripheral fatigue, and the impairment in torque for both conditions could be considered marginal (CON: 10% reduction; GLUT: 5% reduction), we suggest there is limited evidence that glutamine preserves MVC torque to a clinically relevant degree.

To our knowledge, this is the first study to investigate the effect of glutamine supplementation on self-paced exercise performance in the heat. Previous literature has focused primarily on glutamine supplementation during fixed-intensity exercise tasks in the heat (Lambert et al., 2001; Pugh, Sage, et al., 2017; Zuhl et al., 2015; Zuhl et al., 2014). Collectively, this research suggests that increased GI permeability and damage, stemming from strenuous exercise in the heat, can be ameliorated by glutamine, with similar findings in animal models (Singleton & Wischmeyer, 2006). Although the current study did not specifically assess GI permeability, glutamine supplementation was not observed to attenuate the rise in markers of GI damage, I-FABP, compared to a placebo, which is in contrast to the dose-response findings of Pugh, Sage, et al. (2017). However, the considerable difference of within-condition effect sizes for CON ($d = 4.1$; $\text{Pr } d > \text{SESOI} (2.7) = .99$) and GLUT ($d = 1.9$; $\text{Pr } d > \text{SESOI} (2.7) = .32$) provides some evidence for a possible separation due to condition. Further research using larger sample sizes and correction for changes in plasma volume should be undertaken into glutamine

supplementation and its possible role in providing a stabilising and protective effect to the gut mucosa during self-paced exercise in the heat.

This study only provided limited evidence that glutamine supplementation may modulate the release of the pro-inflammatory cytokine, TNF- α , ($d = 0.7$; $\Pr d > \text{SESOI} (0.44) = .60$). This finding is dissimilar to previous research using in-vitro human PBMC models (Wischmeyer et al., 2003) as well as fixed-intensity protocols (Zuhl et al., 2015), and suggests that glutamine does not appear to protect against inflammatory cytokine release (i.e., IL-6 or TNF- α) during short-duration self-paced exercise in the heat. The increased levels of IL-6 in both conditions may have occurred due to the multi-origin nature of the molecule, which is considered both a cytokine and a myokine due to its expression during skeletal muscle contractions (Pedersen et al., 2003). The non-statistical difference in 20TT completion time between conditions would suggest a comparable level of muscle contractile activity, and thus a similar level of IL-6 released. Further, as IL-6 has been implicated in contributing to the feeling of fatigue (Vargas & Marino, 2014), it could be argued that the comparable post-exercise levels of this molecule may explain the similar cycling performance, session RPE and post-exercise VA that were observed between conditions (Tables 1, 3 and 4).

A primary limitation of this study was the small sample size. We attempted to address this limitation by utilising hierarchical models and Bayesian methods (Kruschke & Liddell, 2018; Mengersen et al., 2016). By fitting models in the Bayesian framework we were able to calculate the probability that an effect size exceeded a threshold of interest (i.e., SESOI) by drawing directly from the posterior distribution (Mengersen et al., 2016). Plasma volume change was not calculated for this study, and therefore blood marker data were not corrected for concentration changes arising from dehydration and shifts in plasma volume. While there was no statistical difference in body mass loss between conditions (Table 1), suggesting a comparable level of dehydration, it is conceivable that the observed increase in circulating markers may have been an artefact arising from plasma volume changes.

In summary, this study found that acute glutamine supplementation did not improve 20 km self-paced cycling performance in the heat, preserve neuromuscular function, or attenuate the release of inflammatory cytokines when compared to a placebo. Despite strenuous exercise (mean HR: 88% HR_{max}) and elevated core temperatures (final temperature: ~ 39.0 °C), the exercise task did not induce exertional endotoxemia in either condition. There was some evidence that glutamine supplementation may potentially provide a protective effect for gut mucosa

460 against ischaemic injury, and future studies should continue to investigate the application of glutamine in reducing
461 inflammation and GI damage in prolonged duration exercise or multi-day sporting competitions.

463 **5. Acknowledgements**

464 The authors sincerely thank Mr Logan Trim (Institute of Health and Biomedical Innovation, Queensland
465 University of Technology, Brisbane, Queensland, Australia) for his technical assistance with the immunoassay
466 analysis.

References

- Allen, G. M., Gandevia, S. C., & McKenzie, D. K. (1995). Reliability of measurements of muscle strength and voluntary activation using twitch interpolation. *Muscle & Nerve*, 18(6), 593-600.
- Armstrong, L. E., Pumerantz, A. C., Fiala, K. A., Roti, M. W., Kavouras, S. A., Casa, D. J., & Maresh, C. M. (2010). Human hydration indices: acute and longitudinal reference values. *International Journal of Sport Nutrition and Exercise Metabolism*, 20(2), 145-153.
- Borg, D. N., Osborne, J. O., Stewart, I. B., Costello, J. T., Sims, J. N. L., & Minett, G. M. (2018). The reproducibility of 10 and 20km time trial cycling performance in recreational cyclists, runners and team sport athletes. *Journal of Science and Medicine in Sport*, 21(8), 858-863.
- Borg, G. (1998). *Borg's Perceived Exertion and Pain Scales*. Champaign, IL: Human Kinetics.
- Bosenberg, A. T., Brock-Utne, J. G., Gaffin, S. L., Wells, M. T. B., & Blake, G. T. W. (1988). Strenuous exercise causes systemic endotoxemia. *Journal of Applied Physiology*, 65(1), 106-108.
- Brock-Utne, J. G., Gaffin, S. L., Wells, M. T., Gathiram, P., Sohar, E., James, M. F., . . . Norman, R. J. (1988). Endotoxaemia in exhausted runners after a long-distance race. *South African Medical Journal*, 73(9), 533-536.
- Camus, G., Nys, M., Poortmans, J. R., Venneman, I., Monfils, T., Deby-Dupont, G., . . . Duchateau, J. (1998). Endotoxaemia, production of tumour necrosis factor α and polymorphonuclear neutrophil activation following strenuous exercise in humans. *European Journal of Applied Physiology and Occupational Physiology*, 79(1), 62-68.
- Camus, G., Poortmans, J., Nys, M., Deby-Dupont, G., Duchateau, J., Deby, C., & Lamy, M. (1997). Mild endotoxaemia and the inflammatory response induced by a marathon race. *Clinical Science*, 92(4), 415-422.
- Castell, L. M. (2003). Glutamine Supplementation In Vitro and In Vivo, in Exercise and in Immunodepression. [journal article]. *Sports Medicine*, 33(5), 323-345.
- Cohen, J. (1988). *Statistical power analysis for the behavioral sciences* (2nd ed.). Hillsdale, NJ: L. Erlbaum Associates.
- Dantzer, R. (2004). Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. *European Journal of Pharmacology*, 500(1), 399-411.

- De-Souza, D. A., & Greene, L. J. (2005). Intestinal permeability and systemic infections in critically ill patients: Effect of glutamine. *Critical Care Medicine*, 33(5), 1125-1135.
- De Pauw, K., Roelands, B., Cheung, S. S., De Geus, B., Rietjens, G., & Meeusen, R. (2013). Guidelines to classify subject groups in sport-science research. *International Journal of Sports Physiology and Performance*, 8(2), 111-122.
- Foster, C., Florhaug, J. A., Franklin, J., Gottschall, L., Hrovatin, L. A., Parker, S., . . . Dodge, C. (2001). A new approach to monitoring exercise training. *Journal of Strength and Conditioning Research*, 15(1), 109-115.
- Gagge, A. P., Stolwijk, J. A., & Hardy, J. D. (1967). Comfort and thermal sensations and associated physiological responses at various ambient temperatures. *Environmental Research*, 1(1), 1-20.
- Galloway, S. D. R., & Maughan, R. J. (1997). Effects of ambient temperature on the capacity to perform prolonged cycle exercise in man. *Medicine & Science in Sports & Exercise*, 29(9), 1240-1249.
- Gill, S. K., Teixeira, A., Rama, L., Prestes, J., Rosado, F., Hankey, J., . . . Costa, R. J. (2015). Circulatory endotoxin concentration and cytokine profile in response to exertional-heat stress during a multi-stage ultra-marathon competition. *Exercise Immunology Review*, 21, 114-128.
- Guy, H. J., & Vincent, E. G. (2018). Nutrition and Supplementation Considerations to Limit Endotoxemia When Exercising in the Heat. *Sports*, 6(1), 12.
- Iso 9886. (2004). *Evaluation of thermal strain by physiological measurements*. Geneva: International Organization for Standardization.
- James, K. E., Bloch, D. A., Lee, K. K., Kraemer, H. C., & Fuller, R. K. (1996). An index for assessing blindness in a multi-centre clinical trial: Disulfiram for alcohol cessation - a VA cooperative study. *Statistics in Medicine*, 15(13), 1421-1434.
- Jeukendrup, A. E., Vet-Joop, K., Sturk, A., Stegen, J. H. J. C., Senden, J., Saris, W. H. M., & Wagenmakers, A. J. M. (2000). Relationship between gastro-intestinal complaints and endotoxaemia, cytokine release and the acute-phase reaction during and after a long-distance triathlon in highly trained men. *Clinical Science*, 98(1), 47-55.
- Kruschke, J. K., & Liddell, T. M. (2018). Bayesian data analysis for newcomers. *Psychonomic Bulletin & Review*, 25(1), 155-177.

- Lambert, G. P. (2008). Intestinal barrier dysfunction, endotoxemia, and gastrointestinal symptoms: the 'canary in the coal mine' during exercise-heat stress? *Medicine and Sport Science*, 53, 61-73.
- Lambert, G. P. (2009). Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects. *Journal of Animal Science*, 87(14 Suppl.), E101-E108.
- Lambert, G. P., Broussard, L. J., Mason, B. L., Mauermann, W. J., & Gisolfi, C. V. (2001). Gastrointestinal permeability during exercise: effects of aspirin and energy-containing beverages. *Journal of Applied Physiology*, 90(6), 2075-2080.
- Lambert, G. P., Lang, J., Bull, A., Pfeifer, P. C., Eckerson, J., Moore, G., . . . O'brien, J. (2008). Fluid Restriction during Running Increases GI Permeability. *International Journal of Sports Medicine*, 29(03), 194-198.
- Lambert, G. P., Murray, R., Eddy, D., Scott, W., Laird, R., & Gisolfi, C. V. (1999). Intestinal permeability following the 1998 Ironman Triathlon. *Medicine & Science in Sports & Exercise*, 31(Supplement), S318.
- Lim, C. L., & Mackinnon, L. T. (2006). The roles of exercise-induced immune system disturbances in the pathology of heat stroke : the dual pathway model of heat stroke. *Sports Medicine*, 36(1), 39-64.
- Lim, C. L., Pyne, D., Horn, P., Kalz, A., Saunders, P., Peake, J., . . . Mackinnon, L. T. (2009). The effects of increased endurance training load on biomarkers of heat intolerance during intense exercise in the heat. *Applied Physiology, Nutrition and Metabolism*, 34(4), 616-624.
- Marchbank, T., Davison, G., Oakes, J. R., Ghatei, M. A., Patterson, M., Moyer, M. P., & Playford, R. J. (2011). The nutraceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. [10.1152/ajpgi.00281.2010]. *American Journal of Physiology - Gastrointestinal and Liver Physiology*, 300(3), G477-G484.
- Mengersen, K. L., Drovandi, C. C., Robert, C. P., Pyne, D. B., & Gore, C. J. (2016). Bayesian Estimation of Small Effects in Exercise and Sports Science. *PloS One*, 11(4), e0147311.
- Morrison, S. A., Cheung, S. S., & Cotter, J. D. (2014). Bovine colostrum, training status, and gastrointestinal permeability during exercise in the heat: a placebo-controlled double-blind study. *Applied Physiology, Nutrition, and Metabolism*, 39(9), 1070-1082.

595 Nybo, L., Rasmussen, P., & Sawka, M. N. (2014). Performance in the heat-physiological
596 factors of importance for hyperthermia-induced fatigue. *Comprehensive Physiology*,
597 4(2), 657-689.

598
599 Øktedalen, O., Lunde, O. C., Opstad, P. K., Aabakken, L., & Kvernebo, K. (1992). Changes
600 in the gastrointestinal mucosa after long-distance running. *Scandinavian Journal of*
601 *Gastroenterology*, 27(4), 270-274.

602
603 Osborne, J. O., Stewart, I. B., Beagley, K. W., & Minett, G. M. (2019). The effect of cycling
604 in the heat on gastrointestinal-induced damage and neuromuscular fatigue. *European*
605 *Journal of Applied Physiology*, 119(8), 1829-1840.

606
607 Pedersen, B. K., Steensberg, A., Fischer, C., Keller, C., Keller, P., Plomgaard, P., . . . Saltin,
608 B. (2003). Searching for the exercise factor: is IL-6 a candidate? *Journal of Muscle*
609 *Research and Cell Motility*, 24(2), 113.

610
611 Périard, J. D., Christian, R. J., Knez, W. L., & Racinais, S. (2014). Voluntary muscle and
612 motor cortical activation during progressive exercise and passively induced
613 hyperthermia. *Experimental Physiology*, 99(1), 136-148.

614
615 Périard, J. D., Cramer, M. N., Chapman, P. G., Caillaud, C., & Thompson, M. W. (2011).
616 Neuromuscular function following prolonged intense self-paced exercise in hot
617 climatic conditions. *European Journal of Applied Physiology*, 111(8), 1561-1569.

618
619 Pfeiffer, B., Cotterill, A., Grathwohl, D., Stellingwerff, T., & Jeukendrup, A. E. (2009). The
620 effect of carbohydrate gels on gastrointestinal tolerance during a 16-km run.
621 *International Journal of Sport Nutrition and Exercise Metabolism*, 19(5), 485-503.

622
623 Pugh, J. N., Impey, S. G., Doran, D. A., Fleming, S. C., Morton, J. P., & Close, G. L. (2017).
624 Acute high-intensity interval running increases markers of gastrointestinal damage
625 and permeability but not gastrointestinal symptoms. *Applied Physiology, Nutrition*
626 *and Metabolism*, 42(9), 941-947.

627
628 Pugh, J. N., Sage, S., Hutson, M., Doran, D. A., Fleming, S. C., Highton, J., . . . Close, G. L.
629 (2017). Glutamine supplementation reduces markers of intestinal permeability during
630 running in the heat in a dose-dependent manner. *European Journal of Applied*
631 *Physiology*, 117(12), 2569-2577.

632
633 Rao, R., & Samak, G. (2012). Role of Glutamine in Protection of Intestinal Epithelial Tight
634 Junctions. *Journal of Epithelial Biology & Pharmacology*, 5(Suppl. 1-M7), 47-54.

635
636 Selkirk, G. A., Mclellan, T. M., Wright, H. E., & Rhind, S. G. (2008). Mild endotoxemia,
637 NF-kappa B translocation, and cytokine increase during exertional heat stress in

- trained and untrained individuals. *American Journal of Physiology - Regulatory, Integrative and Comparative Physiology*, 295(2), R611-R623.
- Singleton, K. D., & Wischmeyer, P. E. (2006). Oral glutamine enhances heat shock protein expression and improves survival following hyperthermia. *Shock*, 25(3), 295-299.
- Tatterson, A. J., Hahn, A. G., Martini, D. T., & Febbraio, M. A. (2000). Effects of heat stress on physiological responses and exercise performance in elite cyclists. *Journal of Science and Medicine in Sport*, 3(2), 186-193.
- Todd, G., Butler, J. E., Taylor, J. L., & Gandevia, S. C. (2005). Hyperthermia: a failure of the motor cortex and the muscle. *The Journal of physiology*, 563(2), 621-631.
- Tucker, R. (2008). Thermoregulation, fatigue and exercise modality. *Medicine and Sport Science*, 53, 26-38.
- Van Wijck, K., Lenaerts, K., Van Loon, L. J., Peters, W. H., Buurman, W. A., & Dejong, C. H. (2011). Exercise-induced splanchnic hypoperfusion results in gut dysfunction in healthy men. *PloS One*, 6(7), e22366.
- Vargas, N., & Marino, F. (2017). Neuroinflammation, cortical activity, and fatiguing behaviour during self-paced exercise. *Pflugers Arch - Eur J Physiol*, 470(2), 413-426.
- Vargas, N. T., & Marino, F. (2014). A neuroinflammatory model for acute fatigue during exercise. *Sports Medicine*, 44(11), 1479-1487.
- Wischmeyer, P. E., Riehm, J., Singleton, K. D., Ren, H., Musch, M. W., Kahana, M., & Chang, E. B. (2003). Glutamine attenuates tumor necrosis factor- α release and enhances heat shock protein 72 in human peripheral blood mononuclear cells. *Nutrition*, 19(1), 1-6.
- Yeh, Y. J., Law, L. Y. L., & Lim, C. L. (2013). Gastrointestinal response and endotoxemia during intense exercise in hot and cool environments. *European Journal of Applied Physiology*, 113(6), 1575-1583.
- Young, A. J., Sawka, M. N., Epstein, Y., Decristofano, B., & Pandolf, K. B. (1987). Cooling different body surfaces during upper and lower body exercise. *Journal of Applied Physiology*, 63(3), 1218-1223.
- Ziegler, T. R., Benfell, K., Smith, R. J., Young, L. S., Brown, E., Ferrari-Baliviera, E., . . . Wilmore, D. W. (1990). Safety and Metabolic Effects of L-Glutamine Administration in Humans. *Journal of Parenteral and Enteral Nutrition*, 14(4_suppl), 137S-146S.

- 681 Zuhl, M., Dokladny, K., Mermier, C., Schneider, S., Salgado, R., & Moseley, P. (2015). The
682 effects of acute oral glutamine supplementation on exercise-induced gastrointestinal
683 permeability and heat shock protein expression in peripheral blood mononuclear cells.
684 *Cell Stress and Chaperones*, 20(1), 85-93.
- 685
686 Zuhl, M. N., Lanphere, K. R., Kravitz, L., Mermier, C. M., Schneider, S., Dokladny, K., &
687 Moseley, P. L. (2014). Effects of oral glutamine supplementation on exercise-induced
688 gastrointestinal permeability and tight junction protein expression. *Journal of Applied*
689 *Physiology*, 116(2), 183-191.

690

691

692 **Table 1.**
693 Baseline, pre- and post-exercise variables posterior predicted mean [95% credible interval]

Variable	Control	Glutamine
POMS	7 [1, 14]	8 [2, 13]
Resting T _{re} (°C)	37.0 [36.8, 37.2]	37.1 [36.9, 37.3]
Resting T _{sk} (°C)	33.1 [32.9, 33.4]	33.2 [33.0, 33.5]
USG	1.009 [1.000, 1.048]	1.016 [1.000, 1.055]
Urine colour	3 [2, 4]	3 [2, 4]
Baseline body mass (kg)	76.6 [71.0, 81.8]	77.1 [71.5, 82.3]
Pre-post body mass loss (kg)	1.3 [1.1, 1.4]	1.3 [1.0, 1.3]
Pre-post body mass loss (%)	1.6 [1.4, 1.8]	1.5 [1.3, 1.7]
Session RPE (AU)	9 [8, 9]	9 [8, 9]

694 POMS: profile of mood states; T_{re} : rectal temperature; T_{sk}: skin temperature; USG: urine specific gravity; RPE: rating of perceived exertion; AU = arbitrary
695 units.

696

697

698

699 **Table 2.**
700 Gastrointestinal distress incidence and severity post-exercise questionnaire.

GI Distress Symptom	Control	Glutamine
Cramp	n = 0; 0 (0 – 0)	n = 1; 50 (0 – 50)
Nausea	n = 4; 19 (0 – 25)	n = 4; 13 (0 – 12.5)
Urge to defecate	n = 0; 0 (0 – 0)	n = 0; 0 (0 – 0)
Urge to vomit	n = 4; 27 (0 – 50)	n = 3; 12 (0 – 25)
Stitch/pain in gut	n = 3; 33 (0 – 75)	n = 3; 16 (0 – 30)
Flatulence	n = 0; 0 (0 – 0)	n = 0; 0 (0 – 0)

701 n = response rate/12; mean of responders (range).

702

703

704 **Table 3.**

705 Posterior predicted mean [95% credible interval] for time trial variables (mean values for each 20 km time trial).

Variable	Control	Glutamine
Completion time (min:sec)	33:22 [31:52, 34:54]	33:33 [32:02, 35:06]
Power (W)	256 [226, 285]	251 [221, 280]
Cadence (revolutions·min ⁻¹)	97 [91, 103]	98 [92, 104]
Speed (km·h ⁻¹)	36.3 [34.7, 37.8]	36.1 [34.5, 37.6]
Heart rate (beats·min ⁻¹)	167 [166, 173] *	166 [165, 172] *
T _{re} (°C)	38.0 [37.9, 38.2] *	38.0 [38.0, 38.2] *
T _{sk} (°C)	36.0 [36.0, 36.3] *	36.1 [36.0, 36.3] *
RPE (AU)	16 [15, 17] *	16 [16, 17] *
Thermal sensation (AU)	6 [6, 7] *	6 [6, 7] *
Thermal comfort (AU)	4 [3, 4] *	4 [3, 4] *

706 * indicates *time* effect. T_{re}: rectal temperature; T_{sk}: skin temperature; RPE: rating of perceived exertion; AU = arbitrary units.

707

708

709

710

Table 4.

711

Posterior predicted mean [95% credible interval] for pre- and post-20 km time trial neuromuscular variables.

Variable	Pre-Exercise		Post Exercise	
	Control	Glutamine	Control	Glutamine
MVC torque (N·m)	231 [194, 268]	228 [191, 266]	208 [170, 244]* $d = -2.8 [-4.8, -0.9]$ Pr $d < -\text{SESOI} (-1.33) = .94$	217 [180, 254]* $d = -1.4 [-3.4, 0.6]$ Pr $d < -\text{SESOI} (-1.33) = .48$
VA (%)	92.0 [87.6, 96.4]	92.7 [88.5, 97.2]	86.3 [81.9, 90.8]* $d = -3.0 [-5.0, -1.0]$ Pr $d < -\text{SESOI} (-0.51) = .99$	87.6 [83.2, 91.9]* $d = -2.8 [-4.8, -0.8]$ Pr $d < -\text{SESOI} (-0.51) = .98$
EMG VL (%)	-	-	76.9 [64.3, 88.8]	81.5 [69.0, 93.8]
EMG VM (%)	-	-	71.4 [60.9, 81.3]	78.4 [67.8, 88.4]
Pt (N·m)	64 [51, 78]	60 [47, 73]	55 [41, 68]* $d = -3.9 [-5.9, -2.0]$	52 [39, 66]* $d = -3.1 [-5.0, -1.0]$
TPt (ms)	76 [71, 81]	80 [75, 85]	68 [62, 73]* $d = -2.8 [-4.8, -0.8]$	70 [64, 75]* $d = -3.6 [-5.6, -1.6]$
1/2 RT (ms)	64 [52, 75]	62 [50, 74]	41 [21, 53]* $d = -4.7 [-6.6, -2.7]$	45 [34, 57]* $d = -3.5 [-5.5, -1.5]$
CD (ms)	139 [125, 153]	143 [129, 157]	109 [95, 123]* $d = -5.4 [-7.4, -3.4]$	115 [101, 129]* $d = -5.0 [-7.0, -3.0]$
RTD (N·m·s ⁻¹)	850 [659, 1036]	769 [579, 951]	810 [626, 997] $d = -0.92 [-2.8, 1.1]$	761 [572, 944] $d = -0.19 [-2.1, 1.8]$
RR (N·m·s ⁻¹)	590 [443, 733]	556 [408, 702]	631 [481, 774]* $d = 2.6 [0.5, 4.5]$	597 [450, 745]* $d = 1.8 [0.21, 3.7]$

712

* indicates *time* effect. Cohen's d effect size [95% credible interval] and probability (Pr) that this effect size exceeds the smallest effect size of interest (SESOI) is presented for relevant time parameter comparisons.

713

714

MVC: maximum voluntary contraction; VA: voluntary activation; EMG: electromyography; VL: vastus lateralis; VM: vastus medialis; Pt: peak twitch torque; TPt: time to peak torque; 1/2 RT: half relaxation time; CD: contraction duration; RTD: rate of torque development; RR: rate of relaxation.

715

716

717

Table 5.

718

Posterior predicted mean [95% credible interval] for blood marker variables.

Variable	Pre-Exercise		Post Exercise	
	Control	Glutamine	Control	Glutamine
Endotoxin (EU·mL ⁻¹)	0.22 [0.00, 1.19]	0.04 [0.00, 0.82]	0.87 [0.04, 1.72] <i>d</i> : 1.1 [-0.84, 3.1]	0.08 [0, 0.85] <i>d</i> : 0.25 [-1.8, 2.2]
IL-6 (pg·mL ⁻¹)	1.0 [0.0, 2.0]	0.7 [0.0, 1.7]	4.2 [3.2, 5.2] * <i>d</i> : 4.7 [2.7, 6.7]	3.3 [2.3, 4.3] * <i>d</i> : 4.1 [2.1, 6.1]
TNF-α (pg·mL ⁻¹)	3.8 [2.9, 4.8]	3.3 [2.3, 4.2]	5.6 [4.6, 6.6] * <i>d</i> : 2.7 [0.7, 4.7] Pr <i>d</i> > SESOI (0.44): .99	3.8 [2.8, 4.7] * <i>d</i> : 0.7 [-1.2, 2.8] Pr <i>d</i> > SESOI (0.44): .60
I-FABP (ng·mL ⁻¹)	0.533 [0.337, 0.728]	0.610 [0.413, 0.808]	0.973 [0.780, 1.163] * <i>d</i> : 4.1 [2.2, 6.1] Pr <i>d</i> > SESOI (2.66): .99	0.815 [0.621, 1.017] * <i>d</i> : 1.9 [0.0, 3.9] Pr <i>d</i> > SESOI (2.66): .32

719

* indicates a *time* effect. Cohen's *d* effect size [95% credible interval] and probability (Pr) that this effect size exceeds the smallest effect size of interest (SESOI) is presented for relevant time parameter comparisons.

720

721

EU: endotoxin units; IL-6: interleukin-6; TNF-α: tumour necrosis factor alpha; I-FABP: intestinal fatty acid binding protein